NICE to Charge up to $282,000 for New Drug Assessments

The UK’s National Institute of Health and Care Excellence (NICE) plans to start charging pharmaceutical companies new fees for each cost-effectiveness assessment for a new medicine beginning next year. The new fees could be up to $282,000! Find out more here. (Source: Zachary Brennan, RAPS, 10/3/16)

You might also be interested in:

PAI and BresMed Join Forces to Support Expanded Use of More… 07/22/2019
ICER Signs Multi-Year Deal to Use New Cloud-Based Analytic… 02/20/2020
Scientific Research And Development Services Global Market… 06/19/2020
Jeff Anderson Joins OPEN Health as European Lead for OPEN VIE… 06/16/2020
Biomarkers and Companion diagnostics: Payer Insights 09/26/2019
Real World Evidence (RWE) Solutions Market by Component,… 02/05/2020
The Future of Personalised Medicine: The Role of Simulation… 01/25/2020